STOCKHOLDERS' EQUITY |
STOCKHOLDERS' EQUITY Stock Issuances When the Company completes a business combination or asset acquisition, which are further described in Note 18, the Company may issue shares of the Company's common stock. Stock issuances in relation to acquisitions during the years ended December 31, 2023, 2022 and 2021 were as follows: | | | | | | | | | | | | | | | | | | | | | (In thousands, except for per share data) | | Period of Acquisition | | Shares Issued | | Fair Value of Shares Issued | OmicEra | | May 2022 | | 265,186 | | $ | 14,792 | | PreventionGenetics | | December 2021 | | 1,070,410 | | 84,252 | | Ashion | | April 2021 | | 125,444 | | 16,224 | | Thrive | | January 2021 | | 9,323,266 | | 1,191,420 | | TARDIS license | | January 2021 | | 191,335 | | 27,263 | |
Changes in Accumulated Other Comprehensive Income (Loss) The amount recognized in AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows: | | | | | | | | | | | | | | | | | | | | | (In thousands) | | Cumulative Translation Adjustment | | Unrealized Gain (Loss) on Securities (1) | | AOCI | Balance at January 1, 2021 | | $ | — | | | $ | 526 | | | $ | 526 | | Other comprehensive income (loss) before reclassifications | | 23 | | | (1,648) | | | (1,625) | | Amounts reclassified from accumulated other comprehensive income (loss) | | — | | | (514) | | | (514) | | Net current period change in accumulated other comprehensive loss | | 23 | | | (2,162) | | | (2,139) | | Income tax benefit related to items of other comprehensive loss | | — | | | 170 | | | 170 | | Balance at December 31, 2021 | | $ | 23 | | | $ | (1,466) | | | $ | (1,443) | | Other comprehensive income (loss) before reclassifications | | 30 | | | (4,049) | | | (4,019) | | Amounts reclassified from accumulated other comprehensive income (loss) | | — | | | 226 | | | 226 | | Net current period change in accumulated other comprehensive loss | | 30 | | | (3,823) | | | (3,793) | | Balance at December 31, 2022 | | $ | 53 | | | $ | (5,289) | | | $ | (5,236) | | Other comprehensive income (loss) before reclassifications | | 1,321 | | | 1,416 | | | 2,737 | | Amounts reclassified from accumulated other comprehensive income (loss) | | — | | | 3,927 | | | 3,927 | | Net current period change in accumulated other comprehensive income (loss) | | 1,321 | | | 5,343 | | | 6,664 | | Balance at December 31, 2023 | | $ | 1,374 | | | $ | 54 | | | $ | 1,428 | |
_________________________________ (1)There was no tax impact from the amounts recognized in AOCI for the years ended December 31, 2023 and 2022. Amounts reclassified from AOCI for the years ended December 31, 2023, 2022 and 2021 were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Year Ended December 31, | Details about AOCI Components (In thousands) | | Affected Line Item in the Statements of Operations | | 2023 | | 2022 | | 2021 | Change in value of available-for-sale investments | | | | | | | | | Sales and maturities of available-for-sale investments | | Investment income (loss) | | $ | 3,927 | | | $ | 226 | | | $ | (514) | | Total reclassifications | | | | $ | 3,927 | | | $ | 226 | | | $ | (514) | |
|